Change - Announcement of Appointment::Appointment of Lead Independent Director and Nomination & Compensation Committee member-Mr Allen Lew

Issuer & Securities

Issuer/ Manager
RAFFLES MEDICAL GROUP LTD
Securities
RAFFLES MEDICAL GROUP LTD - SG1CH4000003 - BSL
Stapled Security
No

Announcement Details

Announcement Title
Change - Announcement of Appointment
Date &Time of Broadcast
22-Apr-2024 18:38:06
Status
New
Announcement Sub Title
Appointment of Lead Independent Director and Nomination & Compensation Committee member-Mr Allen Lew
Announcement Reference
SG240422OTHRZ542
Submitted By (Co./ Ind. Name)
Kimmy Goh
Designation
Company Secretary
Description (Please provide a detailed description of the event in the box below)
Appointment of the Lead Independent Director and a member of the Nomination & Compensation Committee

Additional Details

Date Of Appointment
27/04/2024
Name Of Person
Lew Yoong Keong Allen
Age
68
Country Of Principal Residence
Singapore
Date of last re-appointment (if applicable)
26/04/2021
The Board's comments on this appointment (including rationale, selection criteria, board diversity considerations, and the search and nomination process)
The Board has considered the Nomination & Compensation Committee's (NCC) recommendation and assessments of Mr Lew Yoong Keong Allen's qualifications and experiences and is satisfied that he will contribute relevant knowledge, skills and experience to the Board, the NCC as well as the Audit & Risk Committee (ARC).

Mr Lew will continue to be the Chairman of the ARC. The Board considers Mr Lew to be independent for the purpose of Rule 704(8) of the Listing Manual of the Singapore Exchange Securities Trading Limited.
Whether appointment is executive, and if so, the area of responsibility
Non-Executive
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Independent Director wef 28 Oct 2020
ARC Member wef 19 Feb 2021
ARC Chairman wef 1 May 2021
Lead Independent Director and NCC Member wef 27 Apr 2024
Professional qualifications
- Bachelor of Electrical Engineering, University of Western Australia
- Master of Science (Management), Massachusetts Institute of Technology, USA
Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/ or substantial shareholder of the listed issuer or any of its principal subsidiaries
Nil
Conflict of interests (including any competing business)
Nil
Working experience and occupation(s) during the past 10 years
Singapore Telecommunications Limited
- Senior Advisor (2021 to 2023)
- CEO Group Strategy & Business Development / Country Chief Officer Thailand (2020 to 2021)
- CEO, Consumer Australia and CEO Optus (2014 to 2020)
Undertaking submitted to the listed issuer in the form of Appendix 7.7 (Listing Rule 704(7)) Or Appendix 7H (Catalist Rule 704(6))
Yes
Shareholding interest in the listed issuer and its subsidiaries?
Yes
Shareholding Details
Direct interest: 200,000 Raffles Medical Group Ltd Ordinary Shares

Deemed interest: Nil

640,000 share options (vested and unvested)
granted pursuant to the Raffles Medical Group (2020) Share Option Scheme
# These fields are not applicable for announcements of appointments pursuant to Listing Rule 704 (9) or Catalist Rule 704 (8).
Past (for the last 5 years)
Please refer to Appendix 1 attached.
Present
Please refer to Appendix 2 attached.
(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?
No
(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?
No
(c) Whether there is any unsatisfied judgment against him?
No
(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?
No
(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?
No
(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?
No
(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?
No
(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?
No
(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?
No
(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of :-
(i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or
No
(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or
No
(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or
No
(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?
No
(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?
No
Any prior experience as a director of an issuer listed on the Exchange?
Yes
If Yes, Please provide details of prior experience
Mr Lew is currently the Non-Executive and Independent Director of the Company since 28 October 2020 and Member of the Audit & Risk Committee (ARC) since 19 February 2021 and Chairman of the ARC from 1 May 2021.

Attachments

Appendix 1 - Mr Allen Lew - 22 April 2024.pdf
Appendix 2 - Mr Allen Lew - 22 April 2024.pdf
Total size =235K